OCUGEN, INC. Payments to Acquire Investments
OCUGEN, INC. (OCGN) reported Payments to Acquire Investments of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-19.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2021-03-19
- OCUGEN, INC. payments to acquire investments for the quarter ending 2020-12-31 was $0.00.
- OCUGEN, INC. payments to acquire investments for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. payments to acquire investments for the quarter ending 2019-12-31 was -$6.79K.
- OCUGEN, INC. payments to acquire investments for the quarter ending 2019-09-30 was $2.20M.
- OCUGEN, INC. payments to acquire investments for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- OCUGEN, INC. payments to acquire investments for fiscal 2019 was $2.33M.
- OCUGEN, INC. payments to acquire investments for fiscal 2018 was $0.00.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $0.00 derived: sum of 2 quarters · filed 2021-03-19 | $0.00 10-K · filed 2021-03-19 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 | |||
| 2019-12-31 | -$6.79K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $2.20M derived: sum of 2 quarters · filed 2021-03-19 | $2.33M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $2.33M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $130.00K 10-Q · filed 2020-08-14 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |